Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 18 (2002), Issue 2, Pages 83-90
http://dx.doi.org/10.1155/2002/438745

Biomarkers and Surrogate Endpoints: How and When might They Impact Drug Development?

Chetan D. Lathia

Clinical Pharmacology, Bayer Corporation, West Haven, CT 06516, USA

Received 18 September 2002; Accepted 18 September 2002

Copyright © 2002 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Chetan D. Lathia, “Biomarkers and Surrogate Endpoints: How and When might They Impact Drug Development?,” Disease Markers, vol. 18, no. 2, pp. 83-90, 2002. doi:10.1155/2002/438745